Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Sells $281,500.00 in Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Jeffrey William Henderson sold 5,000 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total transaction of $281,500.00. Following the sale, the director now owns 38,611 shares in the company, valued at approximately $2,173,799.30. This trade represents a 11.46 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Jeffrey William Henderson also recently made the following trade(s):

• On Monday, January 6th, Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $50.01, for a total value of $500,100.00.

Halozyme Therapeutics Stock Up 0.5 %

HALO opened at $57.94 on Friday. The business has a 50 day moving average price of $51.18 and a two-hundred day moving average price of $54.38. Halozyme Therapeutics, Inc. has a 52 week low of $34.36 and a 52 week high of $65.53. The company has a market cap of $7.37 billion, a PE ratio of 19.19, a P/E/G ratio of 0.43 and a beta of 1.25. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32.

Institutional Investors Weigh In On Halozyme Therapeutics

Large investors have recently modified their holdings of the stock. Geode Capital Management LLC increased its stake in Halozyme Therapeutics by 1.0% in the 3rd quarter. Geode Capital Management LLC now owns 3,060,131 shares of the biopharmaceutical company’s stock valued at $175,194,000 after buying an additional 30,901 shares during the period. Congress Asset Management Co. boosted its holdings in shares of Halozyme Therapeutics by 446.5% in the third quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock valued at $139,298,000 after acquiring an additional 1,988,238 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Halozyme Therapeutics by 0.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,783,177 shares of the biopharmaceutical company’s stock worth $85,254,000 after acquiring an additional 9,780 shares during the period. Boston Trust Walden Corp raised its holdings in Halozyme Therapeutics by 28.0% during the fourth quarter. Boston Trust Walden Corp now owns 874,081 shares of the biopharmaceutical company’s stock worth $41,790,000 after purchasing an additional 191,465 shares in the last quarter. Finally, Victory Capital Management Inc. lifted its position in Halozyme Therapeutics by 60.0% in the fourth quarter. Victory Capital Management Inc. now owns 650,751 shares of the biopharmaceutical company’s stock valued at $31,112,000 after purchasing an additional 243,940 shares during the period. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on HALO. Wells Fargo & Company decreased their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. HC Wainwright restated a “buy” rating and issued a $70.00 price objective on shares of Halozyme Therapeutics in a research note on Tuesday. Piper Sandler boosted their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a report on Friday, January 10th. Finally, JMP Securities upped their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research report on Friday, November 1st. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $60.89.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.